Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 [Seeking Alpha]
Indivior PLC (INDV)
Company Research
Source: Seeking Alpha
Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x. With new competition from Brixadi, Sublocade maintains 80% market share across new patients. With LAI's low-7% penetration in BMAT, having both options on the market raises awareness for both drugs. The BMAT (Buprenorphine-Medically-Assisted-Treatment) market is expected to grow at a 9.9% CAGR over the next 8 years in the US. ABEMOS/iStock via Getty Images Introduction / Quick Background This is the third time I've written about Indivior ( NASDAQ: INDV ) and it's the most bullish I have been on th
Show less
Read more
Impact Snapshot
Event Time:
INDV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INDV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INDV alerts
High impacting Indivior PLC news events
Weekly update
A roundup of the hottest topics
INDV
News
- Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024PR Newswire
- Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of IndiviorPR Newswire
- Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention MonthPR Newswire
- Indivior PLC (NASDAQ: INDV) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, up previously from $15.00.MarketBeat
- Indivior PLC (INDV) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
INDV
Sec Filings
- 11/19/24 - Form 6-K
- 11/18/24 - Form 6-K
- 11/15/24 - Form SC
- INDV's page on the SEC website